Alkermes
Alkermes snaps up Rodin Therapeutics for a potential $950 million
November 19, 2019Manufacturing and Production, Sales and Marketing Alkermes, Rodin Therapeutics, pharma
Dublin’s Alkermes is set to acquire US firm Rodin Therapeutics in a deal worth a potential $950 million, it has …
FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis
October 30, 2019Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma
The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …
Biogen & Alkermes’ multiple sclerosis drug proves “statistically superior” to Tecfidera at Phase 3
July 31, 2019Research and Development Alkermes, Biogen, multiple sclerosis, pharma
Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s …
FDA knocks back Alkermes’ opioid-based depression therapy over lack of evidence
February 4, 2019Sales and Marketing Alkermes, FDA, major depressive disorder, pharma, rejection
Alkermes experimental opioid-based depression therapy ALKS 5461 has been rejected by the FDA, it has emerged, in the adjunctive treatment …
Committee advises against FDA approval of Alkermes’ novel depression drug
November 2, 2018Medical Communications, Sales and Marketing Alkermes, FDA, depression, pharma
Alkermes has been knocked back with the disappointing, though not entirely unexpected, news that the FDA-appointed Psychopharmacologic Drugs Advisory Committee …
FDA flip-flops on Alkermes’ drug application
April 17, 2018Manufacturing and Production, Sales and Marketing Alkermes, FDA, biotech, drugs, pharma, pharmaceutical
Two weeks ago, it looked like the hopes for Alkermes’ ALKS 5461 receiving approval would rely on returning to the …
Alkermes sent reeling as FDA refuses review of depression treatment
April 3, 2018Manufacturing and Production, Research and Development, Sales and Marketing Alkermes, FDA, depression, major depressive disorder, pharma
Alkermes shares were knocked down to their lowest level since October 2016 after it was revealed that the FDA had …
Phase III depression trial success for Alkermes
October 24, 2016Research and Development, Sales and Marketing ALKS 5461, Alkermes, major depressive disorder
Biopharma company Alkermes has announced the success of its ALKS 5461 treatment in a Phase III study for the treatment …
Alkermes aims to take the next biotech step
December 3, 2015Medical Communications, Research and Development Alkermes
“We think we can be the next Biogen, or a Celgene or a Vertex – we have that much firepower …
FDA approves Alkermes schizophrenia treatment
October 6, 2015Research and Development Alkermes, Aristada, FDA, schizophrenia
The US Food and Drug Administration (FDA) has approved Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada …
Alkermes schizophrenia drug shines in Phase III
April 8, 2014Medical Communications, Research and Development, Sales and Marketing Abilify, Alkermes, aripiprazole, schizophrenia
Alkermes’ investigational schizophrenia drug has met its primary endpoint in a pivotal trial, leading the firm to seek regulatory approval …
Alkermes and Elan Drug Technologies complete merger
September 19, 2011Manufacturing and Production Alkermes, Elan, pharma manufacturing news
The contract manufacturing and development unit of Irish drugmaker Elan has completed a near-$1 billion merger with drug delivery specialist …
Elan sells formulations unit to Alkermes for $960m
May 10, 2011Manufacturing and Production Alkermes, Elan
Irish drugmaker Elan has finally found a buyer for its Elan Drug Technologies unit, which has been on and off …
Novo’s Victoza beats Bydureon in head-to-head trial
March 4, 2011Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes
Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …
Latest content
FibroFind appoints Lee Borthwick as CEO
